SENZUMODERN REBIRTHMy account Semaglutide
Also known as Ozempic · Rybelsus · sema · Wegovy
Large randomized trials show clinically meaningful weight reduction. In adults with established cardiovascular disease and overweight or obesity without diabetes, SELECT also found fewer major cardiovascular events. Results and indications differ by product and formulation.
- Evidence maturity
- Established record
- Regulatory status
- FDA approved
- Recorded outcomes
- 3
- Indexed sources
- 3
This profile does not recommend a compound, dose, supplier, or treatment plan. Discuss personal decisions with a qualified clinician who knows your history.
Summary
A GLP-1 receptor agonist with FDA-approved products for specific metabolic and cardiovascular indications.
What is Semaglutide being studied for?
Weight management and cardiovascular risk
How is it thought to work?
Activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, reducing glucagon, lowering appetite and caloric intake, and delaying gastric emptying.
Recorded outcomes
3 graded outcomes and 3 sources for Semaglutide.
The graded outcome table, how each grade was decided, the regulatory detail, and every source with its link and identifier open with a free account. No payment details required.
Update history
- Editorial review of the profile and its sources.
- Record last updated in the Senzu database.
- Profile first published.